Vir Biotechnology (VIR) Common Equity (2018 - 2026)

Vir Biotechnology has reported Common Equity for 9 years, with the latest figure at $812.8 million in Q1 2026.

• Quarterly Common Equity fell 22.14% year-over-year to $812.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $812.8 million (down 22.14% YoY) and the FY2025 annual result came in at $765.3 million, down 33.48% from the prior year.
• Common Equity grew to $812.8 million in Q1 2026 per VIR's latest filing, from $765.3 million in the prior quarter.
• Over five years, Common Equity peaked at $2.1 billion in Q3 2022 and troughed at $765.3 million in Q4 2025.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity jumped 207.4% in 2022, then tumbled 35.84% in 2025.
• Over 5 years, Common Equity stood at $2.1 billion in 2022, then dropped by 23.47% to $1.6 billion in 2023, then slipped by 27.66% to $1.2 billion in 2024, then plunged by 33.48% to $765.3 million in 2025, then climbed by 6.21% to $812.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $812.8 million, $765.3 million, and $796.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.